| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 1785 | 2017 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 938 | 2018 |
| Ofatumumab versus teriflunomide in multiple sclerosis SL Hauser, A Bar-Or, JA Cohen, G Comi, J Correale, PK Coyle, AH Cross, ... New England Journal of Medicine 383 (6), 546-557, 2020 | 501 | 2020 |
| Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet 387 (10023), 1075-1084, 2016 | 487 | 2016 |
| Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) H Butzkueven, L Kappos, H Wiendl, M Trojano, T Spelman, I Chang, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (6), 660-668, 2020 | 108 | 2020 |
| Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial BAC Cree, G Cutter, JS Wolinsky, MS Freedman, G Comi, G Giovannoni, ... The Lancet Neurology 19 (12), 988-997, 2020 | 81 | 2020 |
| Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell … B Willekens, S Presas-Rodríguez, MJ Mansilla, J Derdelinckx, WP Lee, ... BMJ open 9 (9), e030309, 2019 | 75 | 2019 |
| Frequency and characterization of movement disorders in anti-IgLON5 disease C Gaig, Y Compta, A Heidbreder, MJ Marti, MJ Titulaer, Y Crijnen, B Högl, ... Neurology 97 (14), e1367-e1381, 2021 | 63 | 2021 |
| Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised … JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, ... The Lancet Neurology 21 (7), 608-619, 2022 | 61 | 2022 |
| Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial RE Gonsette, C Sindic, MB D'hooghe, PP De Deyn, R Medaer, A Michotte, ... Multiple Sclerosis Journal 16 (4), 455-462, 2010 | 61 | 2010 |
| Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis D De Ridder, F Van der Aa, J Debruyne, MB D’hooghe, B Dubois, ... Clinical neurology and neurosurgery 115 (10), 2033-2040, 2013 | 60 | 2013 |
| Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study M D'hooghe, G Van Gassen, D Kos, O Bouquiaux, M Cambron, D Decoo, ... Multiple Sclerosis and Related Disorders 22, 90-96, 2018 | 58 | 2018 |
| The effectiveness of a self-management occupational therapy intervention on activity performance in individuals with multiple sclerosis-related fatigue: a randomized-controlled … D Kos, M Duportail, J Meirte, M Meeus, MB D’hooghe, G Nagels, ... International Journal of Rehabilitation Research 39 (3), 255-262, 2016 | 58 | 2016 |
| What is in a name? Comparing diagnostic criteria for chronic fatigue syndrome with or without fibromyalgia M Meeus, K Ickmans, F Struyf, D Kos, L Lambrecht, B Willekens, P Cras, ... Clinical rheumatology 35, 191-203, 2016 | 52 | 2016 |
| Myoclonus and cerebellar ataxia following COVID‐19 F Dijkstra, T Van den Bossche, B Willekens, P Cras, D Crosiers Movement disorders clinical practice 7 (8), 974, 2020 | 48 | 2020 |
| IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes M Montagna, R Amir, I De Volder, M Lammens, J Huyskens, B Willekens Frontiers in neurology 9, 329, 2018 | 47 | 2018 |
| Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors K Thewissen, AH Nuyts, N Deckx, BV Wijmeersch, G Nagels, M D’hooghe, ... Multiple sclerosis journal 20 (5), 548-557, 2014 | 44 | 2014 |
| Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial M Cambron, J Mostert, M D’Hooghe, G Nagels, B Willekens, J Debruyne, ... Multiple Sclerosis Journal 25 (13), 1728-1735, 2019 | 36 | 2019 |
| Beyond the magic bullet: Current progress of therapeutic vaccination in multiple sclerosis B Willekens, N Cools CNS drugs 32 (5), 401-410, 2018 | 34 | 2018 |
| Sativex®(nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience M D’hooghe, B Willekens, V Delvaux, M D’haeseleer, D Guillaume, ... BMC neurology 21 (1), 227, 2021 | 28 | 2021 |
